Assessment of combined antiparasitic drugs praziquantel and albendazole versus albendazole alone in the treatment of active parenchymal neurocysticercosis in Tanzania and Zambia.

REvolution Worldwide S.r.l. Impresa Sociale0 个研究点目标入组 300 人开始时间: 2024年1月31日最近更新: 2024年3月4日

适应症

试验速览

暂无简介。

•Inclusion for screening:
•Living in the study area for a continuous period of 3 years
•Late onset/acquired epilepsy
•Adult aged 18 years and above
•Are willing and able to consent to this study
•Are willing to undergo diagnostic procedures
•Inclusion criteria for the treatment study:
•Adult aged 18 years and above
•Are willing and able to consent to this study
•Meet the definitions of active symptomatic NCC
•Have late onset of epilepsy or history of seizures, epileptic seizures
•Are willing to undergo diagnostic procedures
•Are medically stable enough for trial medication to be initiated
•Are willing to be hospitalized for 11-20 days to receive treatment for NCC
•Are willing to be followed up for one year following receipt of study medication

•The participants will be excluded if;
•Are pregnant or breastfeeding
•Symptomatic NCC with cysts in extra-parenchymal location (sub-arachnoid and/or ventricles)
•Have uncontrolled hypertension and/or diabetes
•Have chronic consuming illness such as cancer or mental handicap to not allow them to follow the study instructions
•Have severe immunodeficiency eg. HIV/AIDS or Autoimmune diseases
•Already known allergies to albendazole
•Subject taking part in another clinical/pharmacological study in the 30 days preceding enrollment

发起方

REvolution Worldwide S.r.l. Impresa Sociale